• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Eyenovia Inc. filed SEC Form 8-K: Changes in Registrant's Certifying Accountant

    5/2/25 5:20:18 PM ET
    $EYEN
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $EYEN alert in real time by email
    false 0001682639 0001682639 2025-05-02 2025-05-02 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    FORM 8-K

     

     

    CURRENT REPORT

    Pursuant to Section 13 or 15(d)

    of the Securities Exchange Act of 1934

     

    Date of Report (Date of earliest event reported): May 2, 2025

     

     

    EYENOVIA, INC.

    (Exact Name of Registrant as Specified in its Charter)

     

     

    Delaware   001-38365   47-1178401
    (State or other jurisdiction
    of incorporation)
      (Commission
    File Number)
      (IRS Employer
    Identification No.)

     

    23461 South Pointe Drive, Suite 390

    Laguna Hills, CA 92653

    (Address of Principal Executive Offices, and Zip Code)

     

    (833) 393-6684

    Registrant’s Telephone Number, Including Area Code 

     

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

     

    ¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

    ¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

    ¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

    ¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

     

    Securities registered pursuant to Section 12(b) of the Act:

     

    (Title of each class)   (Trading
    Symbol)
      (Name of each exchange
    on which registered)
    Common stock, $0.0001 par value   EYEN   The Nasdaq Stock Market
    (Nasdaq Capital Market)

     

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

     

    Emerging growth company ¨

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

     

     

     

     

     

     

    Item 4.01 Changes in Registrant’s Certifying Accountant.

     

    CBIZ CPAs P.C. (“CBIZ CPAs”) acquired the attest business of Marcum LLP (“Marcum”), effective November 1, 2024. As a result of this transaction, on May 2, 2025, Marcum resigned as the independent registered public accounting firm of Eyenovia, Inc. (the “Company”) and, with the approval of the Audit Committee of the Company’s Board of Directors, CBIZ CPAs was engaged as the Company’s independent registered public accounting firm for the year ending December 31, 2025.

     

    The audit reports of Marcum on the Company’s consolidated financial statements for the fiscal years ended December 31, 2024 and 2023 contained no adverse opinion or disclaimer of opinion and were not qualified or modified as to uncertainty, audit scope or accounting principles, except that the report for the fiscal years ended December 31, 2024 and 2023 included an explanatory paragraph relating to substantial doubt about the Company’s ability to continue as a going concern.

     

    During the fiscal years ended December 31, 2024 and 2023 and the subsequent interim period through May 2, 2025, there were (i) no disagreements (as defined in Item 304(a)(1)(iv) of Regulation S-K and the related instructions) with Marcum on any matter of accounting principles or practices, financial statement disclosure or auditing scope or procedure, which disagreements if not resolved to the satisfaction of Marcum would have caused them to make reference thereto in connection with their reports on the financial statements for such years and (ii) no reportable events (as described in Item 304(a)(1)(v) of Regulation S-K) other than the two material weaknesses that existed as of December 31, 2024 disclosed in the Company’s Annual Report on Form 10-K for the year ended December 31, 2024, as amended, which the Company is taking steps to remediate.

     

    During the fiscal years ended December 31, 2024 and 2023, and through May 2, 2025, neither the Company nor anyone on its behalf consulted with CBIZ CPAs regarding either: (i) the application of accounting principles to a specific transaction, either completed or proposed, or the type of audit opinion that might be rendered on the Company’s financial statements, and neither a written report nor oral advice was provided to the Company that CBIZ CPAs concluded was an important factor considered by the Company in reaching a decision as to the accounting, auditing or financial reporting issue; or (ii) any matter that was either the subject of a disagreement (as defined in Item 304(a)(1)(iv) of Regulation S-K and the related instructions) or any reportable event (as described in Item 304(a)(1)(v) of Regulation S-K).

     

    The Company provided Marcum with a copy of the above statements and requested that Marcum furnish it with a letter addressed to the U.S. Securities and Exchange Commission stating whether or not it agrees with the above statements. A copy of such letter, dated May 2, 2025, is filed as Exhibit 16.1 to this Current Report on Form 8-K.

     

    Item 9.01 Financial Statements and Exhibits.

     

      (d) Exhibits.

     

    Exhibit No.   Description
       
    16.1   Letter from Marcum LLP, dated May 2, 2025, addressed to the Securities and Exchange Commission
       
    104   Cover Page Interactive Data File (embedded within the Inline XBRL document)

     

     

     

     

    SIGNATURE

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.

     

    EYENOVIA, INC.  
         
    By: /s/ Michael Rowe  
    Name: Michael Rowe  
    Title: Chief Executive Officer  

     

    Dated: May 2, 2025

     

     

     

    Get the next $EYEN alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $EYEN

    DatePrice TargetRatingAnalyst
    11/18/2024$12.00 → $2.00Buy → Neutral
    H.C. Wainwright
    More analyst ratings

    $EYEN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Eyenovia downgraded by H.C. Wainwright with a new price target

      H.C. Wainwright downgraded Eyenovia from Buy to Neutral and set a new price target of $2.00 from $12.00 previously

      11/18/24 7:44:30 AM ET
      $EYEN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • HC Wainwright & Co. reiterated coverage on Eyenovia with a new price target

      HC Wainwright & Co. reiterated coverage of Eyenovia with a rating of Buy and set a new price target of $8.00 from $6.00 previously

      4/1/21 6:45:58 AM ET
      $EYEN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Northland Capital initiated coverage on Eyenovia with a new price target

      Northland Capital initiated coverage of Eyenovia with a rating of Outperform and set a new price target of $10.00

      3/1/21 9:11:48 AM ET
      $EYEN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $EYEN
    Leadership Updates

    Live Leadership Updates

    See more
    • Eyenovia Announces Appointment of Experienced Finance and Accounting Executive Andrew Jones as Chief Financial Officer

      NEW YORK, Sept. 03, 2024 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ:EYEN), a commercial-stage ophthalmic company with two FDA-approved products and a late-stage asset in pediatric progressive myopia, today announced the appointment of experienced finance and accounting executive Andrew Jones as Chief Financial Officer. Mr. Jones brings to the Eyenovia team more than 30 years of diverse finance and accounting leadership experience spanning therapeutics and medical technology/devices, most recently serving as Chief Financial Officer of NovaBay Pharmaceuticals, Inc., a publicly traded, commercial stage ophthalmic company. Eyenovia's current CFO, John Gandolfo, is retiring and will remain with

      9/3/24 7:00:00 AM ET
      $EYEN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Eyenovia Announces Appointment of Ophthalmic Industry Veteran Michael Rowe as Chief Executive Officer and Board Member

      NEW YORK, July 27, 2022 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ:EYEN), an ophthalmic pharmaceutical technology company developing a pipeline of late-stage microdose array print (MAP™) therapeutics, today announced the appointment of current Chief Operating Officer Michael Rowe as the Company's new Chief Executive Officer, effective August 1, 2022. Mr. Rowe's appointment follows the company's nationwide search and interviews with multiple candidates. Mr. Rowe has also been appointed to Eyenovia's Board of Directors, increasing the Board to nine seats following recent appointments of Drs. Strahlman and Palanki as new independent directors, announced in July. Eyenovia's current Chief Exec

      7/27/22 8:00:00 AM ET
      $EYEN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Eyenovia Provides Manufacturing Update and Announces Appointment of Bren Kern as SVP of Manufacturing and Operations

      NEW YORK, July 18, 2022 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ:EYEN), an ophthalmic pharmaceutical technology company developing a pipeline of late-stage microdose array print (MAP™) therapeutics, today provided an update on its expanded manufacturing capabilities and also announced the appointment of Bren Kern as Senior Vice President of Manufacturing and Operations. Redwood City, CA Facility The Company today announced that its new manufacturing facility in Redwood City, CA is operational. The facility, which is located in close proximity to Silicon Valley-based vendors and customers, will primarily focus on Optejet® manufacturing finishing operations, including drug loading, label

      7/18/22 8:00:00 AM ET
      $EYEN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $EYEN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Large owner Avenue Capital Management Ii, L.P.

      4 - EYENOVIA, INC. (0001682639) (Issuer)

      6/3/25 9:18:40 PM ET
      $EYEN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • New insider Avenue Capital Management Ii, L.P. claimed ownership of 30,619 shares (SEC Form 3)

      3 - EYENOVIA, INC. (0001682639) (Issuer)

      6/3/25 9:07:19 PM ET
      $EYEN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: Director Strahlman Ellen R was granted 3,000 shares, increasing direct ownership by 176% to 4,706 units (SEC Form 4)

      4/A - EYENOVIA, INC. (0001682639) (Issuer)

      4/29/25 7:58:58 PM ET
      $EYEN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $EYEN
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Executive Officer Rowe Michael M bought $14,077 worth of shares (27,071 units at $0.52), increasing direct ownership by 33% to 109,998 units (SEC Form 4)

      4 - EYENOVIA, INC. (0001682639) (Issuer)

      8/28/24 8:01:36 PM ET
      $EYEN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Executive Officer Rowe Michael M bought $28,500 worth of shares (50,000 units at $0.57), increasing direct ownership by 152% to 82,927 units (SEC Form 4)

      4 - EYENOVIA, INC. (0001682639) (Issuer)

      8/27/24 1:06:37 PM ET
      $EYEN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Large owner Grant Stuart M. bought $1,000,000 worth of shares (1,515,151 units at $0.66), increasing direct ownership by 16% to 10,914,153 units (SEC Form 4)

      4 - EYENOVIA, INC. (0001682639) (Issuer)

      7/3/24 3:18:06 PM ET
      $EYEN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $EYEN
    SEC Filings

    See more

    $EYEN
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Eyenovia Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits

      8-K - EYENOVIA, INC. (0001682639) (Filer)

      6/5/25 8:00:19 AM ET
      $EYEN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 424B5 filed by Eyenovia Inc.

      424B5 - EYENOVIA, INC. (0001682639) (Filer)

      6/2/25 4:01:05 PM ET
      $EYEN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Eyenovia Inc. filed SEC Form 8-K: Results of Operations and Financial Condition

      8-K - EYENOVIA, INC. (0001682639) (Filer)

      5/19/25 5:30:20 PM ET
      $EYEN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Eyenovia Provides Updates on Potential Merger with Betaliq and Development of the Optejet User Filled Device (UFD), and Reports First Quarter 2025 Financial Results

      Eyenovia and Betaliq continue to negotiate a binding merger agreement consistent with the previously announced signed Letter of Intent Reports continued progress on the development of the user-filled Optejet, and remains on track to file for U.S. device regulatory approval in September 2025 Reduced ongoing cash burn by approximately 70% versus prior year and improved debt repayment terms LAGUNA HILLS, Calif., May 19, 2025 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ:EYEN), an ophthalmic technology company developing the proprietary Optejet® topical ophthalmic medication dispensing platform, today provided updates on its potential merger with Betaliq and the ongoing devel

      5/19/25 5:30:00 PM ET
      $EYEN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Eyenovia Provides Development Update on Optejet User Filled Device (UFD)

      NEW YORK, April 10, 2025 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ:EYEN) ("Eyenovia" or the "Company"), an ophthalmic technology company developing and commercializing advanced products leveraging its proprietary Optejet topical ophthalmic medication dispensing platform, today provided an update on recent progress made in the development of the Company's novel Optejet UFD. The user-filled Optejet is designed to work with a variety of topical ophthalmic liquids, including artificial tears and lens rewetting products, spanning multiple billion-dollar markets. Eyenovia continues to advance the Optejet UFD through Verification & Validation (V&V) studies to ensure that the device meets the st

      4/10/25 7:00:00 AM ET
      $EYEN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Eyenovia Enters into Non-Binding Letter of Intent to Effect Reverse Merger with Betaliq

      Combination, if successful, would create a new publicly-listed eye care company combining Betaliq's EyeSol® water-free drug delivery technology for glaucoma with Eyenovia's Optejet® device platform The combined company would continue marketing Eyenovia's FDA-approved products – and plans to in-license additional products to generate near-term revenue NEW YORK, March 20, 2025 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ:EYEN) ("Eyenovia" or the "Company"), an ophthalmic technology company developing and commercializing advanced products leveraging its proprietary Optejet topical ophthalmic medication dispensing platform, today announced that it has entered into a non-binding letter of inten

      3/20/25 7:00:00 AM ET
      $EYEN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $EYEN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13D/A filed by Eyenovia Inc.

      SC 13D/A - EYENOVIA, INC. (0001682639) (Subject)

      12/4/24 4:12:20 PM ET
      $EYEN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Eyenovia Inc.

      SC 13G/A - EYENOVIA, INC. (0001682639) (Subject)

      11/14/24 5:08:44 PM ET
      $EYEN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13D/A filed by Eyenovia Inc.

      SC 13D/A - EYENOVIA, INC. (0001682639) (Subject)

      7/18/24 7:46:49 PM ET
      $EYEN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $EYEN
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    See more
    • FDA Approval for MYDCOMBI issued to EYENOVIA INC.

      Submission status for EYENOVIA INC.'s drug MYDCOMBI (ORIG-1) with active ingredient TROPICAMIDE AND PHENYLEPHRINE HYDROCHLORIDE has changed to 'Approval' on 05/05/2023. Application Category: NDA, Application Number: 215352, Application Classification: Type 5 - New Formulation or New Manufacturer

      5/8/23 1:05:04 PM ET
      $EYEN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $EYEN
    Financials

    Live finance-specific insights

    See more
    • Eyenovia Reports Third Quarter 2024 Financial Results and Provides Corporate Update

      Advanced Phase 3 CHAPERONE study of MicroPine as a treatment of pediatric progressive myopia with preparations for interim analysis this quarter Commenced the manufacture of registration batches of Mydcombi in its second generation Optejet device Announced the U.S. launch and commercial availability of clobetasol propionate ophthalmic suspension 0.05% for the treatment of inflammation and pain following ocular surgery Appointed Andrew Jones as Chief Financial Officer Company to host conference call and webcast today, November 12th, at 4:30 pm ET NEW YORK, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ:EYEN), an ophthalmic technology company developing and commercializing adv

      11/12/24 4:05:00 PM ET
      $EYEN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Eyenovia to Report Third Quarter 2024 Results on Tuesday, November 12th

      NEW YORK, Nov. 07, 2024 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ:EYEN), an ophthalmic technology company developing and commercializing advanced products leveraging its proprietary Optejet topical ophthalmic medication dispensing platform, today announced that the Company will release financial results for the third quarter ended September 30, 2024 on Tuesday, November 12th, 2024, after the markets close. Following the release, Eyenovia management will host a conference call and webcast at 4:30 p.m. ET to review the financial and operating results. Participants should dial 1-877-407-9039 (domestic) or 1-201-689-8470 (international) and reference Conference ID# 13748714. To access t

      11/7/24 7:00:00 AM ET
      $EYEN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Eyenovia Reports Second Quarter 2024 Financial Results and Provides Corporate Update

      Following FDA consultation, announced plans for validation of the Gen-2 Optejet® device and 2025 regulatory submission with Mydcombi™ as lead product Advanced Phase 3 CHAPERONE study of MicroPine as a treatment of pediatric progressive myopia with preparations for analysis in Q4 Commenced sales activities with focus on Mydcombi in 260+ offices and preparations for launch of clobetasol propionate ophthalmic suspension 0.05%, the first new ophthalmic steroid to enter the market in 15 years Announced development collaborations with Formosa, Senju and SGN to leverage the Optejet for the $5 billion global dry eye disease market Company to host conference call and webcast today, August 12th, a

      8/12/24 4:05:00 PM ET
      $EYEN
      Biotechnology: Pharmaceutical Preparations
      Health Care